Boster Immunoleader

antibody

Anti-LRRK2 Antibody

PB9281

100 ug/vial

240 USD

polyclonal

rabbit

human, mouse, rat

Anti-LRRK2 Antibody

PB9281

Polyclonal

Rabbit IgG polyclonal antibody for Leucine-rich repeat serine/threonine-protein kinase 2(LRRK2) detection. Tested with WB in Human;Mouse;Rat.

240 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human, mouse, rat

WB

Concentration: 0.1-0.5μg/ml; Tested Species: Human, Mouse, Rat

WB: The detection limit for LRRK2 is approximately 0.25ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. Other applications have not been tested. Optimal dilutions should be determined by end users.

E.coli-derived human LRRK2 recombinant protein (Position: E10-L350). Human LRRK2 shares 82% amino acid (aa) sequence identity with mouse LRRK2.

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB.

Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is anenzyme that in humans is encoded by the PARK8 gene. It is a member of the leucine-rich repeat kinase family. This gene is mapped to 12q12. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Expression of mutant LRRK2 induced apoptotic cell death in neuroblastoma cells and in mouse cortical neurons. It has been determined that LRRK2 possesses mixed-lineage kinase activity, and LRRK2 also showed autophosphorylation activity. What’s more, LRRK2 has an affinity for lipids or lipid-associated proteins and may play a role in the biogenesis or regulation of membranous intracellular structures in the brain. It is also an IFNG target gene that may be involved in signaling pathways relevant to Crohn disease.

1. Biskup, S., Moore, D. J., Celsi, F., Higashi, S. West, A. B., Andrabi, S. A., Kurkinen, K., Yu, S.-W., Savitt, J. M., Waldvogel, H. J., Faull, R. L. M., Emson, P. C., Torp, R., Ottersen, O. P., Dawson, T. M., Dawson, V. L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60: 557-569, 2006. 2. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, Singleton AB (November 2004). "Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease". Neuron 44 (4): 595–600. 3. West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., Dawson, T. M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Nat. Acad. Sci. 102: 16842-16847, 2005.

LRRK2

Leucine-rich repeat serine/threonine-protein kinase 2

leucine-rich repeat kinase 2

augmented in rheumatoid arthritis 17 antibody AURA17 antibody Dardarin antibody Leucine rich repeat kinase 2 antibody leucine rich repeat serine threonine protein kinase 2 antibody Leucine-rich repeat serine/threonine-protein kinase 2 antibody LRRK 2 antibody LRRK2 antibody LRRK2_HUMAN antibody PARK 8 antibody PARK8 antibody RIPK7 antibody ROCO 2 antibody ROCO2 antibody

Q5S007